Clinical Trials
43 trialsNivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Bristol-Myers Squibb
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
National Cancer Institute (NCI)
A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)
National Cancer Institute (NCI)
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Incyte Corporation
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Merck Sharp & Dohme LLC
A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy
M.D. Anderson Cancer Center
Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer
Emory University
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
National Cancer Institute (NCI)
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
National Cancer Institute (NCI)
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
Emory University
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
MK-3475A-F11
Merck Sharp & Dohme LLC
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
CONTACT-03
Hoffmann-La Roche
CaboPoint
Ipsen
KEYNOTE-564
Merck Sharp & Dohme LLC
CLEAR
Eisai Inc.
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
National Institutes of Health Clinical Center (CC)
KEYNOTE-426
Merck Sharp & Dohme LLC
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
M.D. Anderson Cancer Center
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
University of California, Davis
Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Metastatic Renal Cell Carcinoma
University of Texas Southwestern Medical Center
Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
University of Washington
KEYNOTE-B61
Merck Sharp & Dohme LLC
An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Medtronic Hugoâ„¢ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)
Medtronic - MITG
Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery
University of California, San Francisco
Molecular-Guided Therapy for Childhood Cancer
Milton S. Hershey Medical Center
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC
ImmuneSensor Therapeutics Inc.
S0931
SWOG Cancer Research Network
COSMIC-313
Exelixis
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
Incyte Corporation
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Incyte Corporation
JAVELIN Renal 101
Pfizer
Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)
Stanford University
ABEMA Alone or in COMBO With MK-6482
Dana-Farber Cancer Institute
Post-Marketing Surveillance Study To Observe INLYTA® Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine Practice
Pfizer
CheckMate 9ER
Bristol-Myers Squibb